UFP TechnologiesUFPT
Recorded

UFP Technologies 2026 Q3 Earnings Call

Review the key takeaways and the transcript of this earnings call.

PeriodQ3 2026Duration22 minParticipants7

Transcript

Preview the first fifteen paragraphs, organized by speaker.

Operator

Good day and welcome to UFP Technologies Third Quarter 2026 Earnings Conference Call. All participant lines will be in the listen-only mode. Should you need assistance, please signal a conference specialist by pressing the star key followed by zero. After today's presentation, there will be an opportunity to ask questions. To ask questions, you may press star then one on your telephone keypad. To withdraw your question, please press star then two. Please note that this event is being recorded. I would now like to turn the conference over to Ron Lataille, Senior Vice President, Treasurer, and Chief Financial Officer.

Ron LatailleSVP, Treasurer and CFO

Please go ahead. Thank you, operator.

Ron LatailleSVP, Treasurer and CFO

Good morning, and thank you for joining us on our 2026 Third Quarter Earnings Conference Call. With me on today's call is our CEO, Mitch Rock. Today, we will make some forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, the accuracy of which is subject to risks and uncertainties. Wherever possible, we will try to identify those forward-looking statements by using words such as believe, expect, anticipate, pursue, forecast, and similar expressions. Our forward-looking statements are based on our estimates and assumptions as of today and should not be relied upon as representing our estimates or views on any subsequent date. Please refer to the cautionary statement regarding forward-looking information and the risk factors in our most recent 10-K and 10-Qs, including disclosure of the factors that could cause results to differ materially from those expressed or implied.

Ron LatailleSVP, Treasurer and CFO

During this call, we will discuss non-GAAP financial measures, which include organic sales growth, adjusted gross margin, adjusted operating income, adjusted SG&A, adjusted EPS, and EBITDA, and adjusted EBITDA. A reconciliation of GAAP to non-GAAP measures discussed in this call is contained in the associated press release and is available in the investor relations section of our website. I'll now turn the call over to Mitch.

Mitch RockCEO

Thank you, Ron. Good morning, everyone, and thank you for joining us. Our third quarter reflects solid execution across UFP and steady progress on our long-term growth strategy. Third quarter sales were $172.4 million, up 11.6%. Organic growth was 11.1%. Gross margin increased to 29.4%. Adjusted operating income grew 14.5%, and adjusted earnings per share increased to $2.88. Year-to-date sales are up 10.3% to $500.6 million. MedTech grew 11.7%, and our top five MedTech customers collectively also grew 11.7%. What stands out to me is how broad the growth is. MedTech sales were up 12.5% in the quarter, with demand across the portfolio. One of the real strengths of UFP is that our growth does not depend on any single customer, program, or end market.

Mitch RockCEO

We were proud to be recognized by one of our top five customers with a supplier award for creating value through innovation and cost savings. That's exactly what we're aiming for, line up with where our customers are going long term and help them scale while taking costs out. On operations, we are continuing to make progress. We are scaling new programs in the Dominican Republic. Margins are improving in our legacy UFP operations, and at AJR, we have made significant year-over-year progress both in the U.S. and in the Dominican Republic. That said, we're behind schedule moving AJR activity to the Dominican Republic. We remain committed to finishing those transfers, scaling up operations, and delivering the savings we anticipate. At the same time, we're investing ahead of growth in other parts of the business.

Mitch RockCEO

At DAS Medical, we are adding capacity ahead of anticipated double-digit growth, along with the people and capabilities to support it. We are broadening what we can do. in August, we acquired CI Medical, a niche medical device printing business that prints on injection molded and extruded plastic components. CI Medical serves device development and low-volume, high-mix applications. It's a strong fit with our growing plastics business. We also see an opportunity to expand medical injection molding. Our 2025 investment in TPI gave us a strong initial position in this large and established market, and CI Medical adds the printing capability that goes along with injection molded and extruded components. Together, they expand what we can offer our customers and add value across the UFP platform. Beyond these investments, acquisitions have always been a key part of our growth strategy, and we're positioning UFP to do more.

Mitch RockCEO

We are making progress on several opportunities, and as UFP has grown, so has the size and range of the businesses we can take on. We remain disciplined on strategic fit and valuation. In parallel, we're working to expand our credit facility, which gives us room to invest in high-quality businesses that meet our criteria. Between a strong conservative balance sheet, a bigger team, and our decentralized operating model, we believe we can bring on larger businesses and keep investing in organic growth. As we look to 2027, I'm optimistic. We have strong customer relationships, expanding capabilities, new capacity coming online, meaningful organic growth opportunities, and an active acquisition pipeline. We also have areas where execution needs to improve, and we remain focused on those.

Mitch RockCEO

Our strategy remains consistent: grow with our customers, invest in our people and capabilities, improve our operations, make disciplined acquisitions, and create long-term value for our shareholders. None of this happens without our thousands of team members around the world. I want to thank them for their commitment to our customers, to each other, and to getting better every day. Thank you. With that, I'll turn it over to Ron.

Ron LatailleSVP, Treasurer and CFO

Thank you, Mitch. With regard to operating results, as Mitch mentioned, overall sales were up 11.6%, fueled by strength in the Patient Beds & Handling, cardiovascular, infection control, and orthopedic sub-markets. Organic sales growth for the quarter was strong at 11.1% as our launch programs accelerate, and we continue to improve efficiencies at AJR. Gross profit as a percentage of sales, or gross margin, increased to 29.4% from 27.7% last year. This improvement was despite continued margin headwind at AJR, as high-labor products scheduled to be transferred to the Dominican Republic continues to be contingent on customer qualification. SG&A expenses for our third quarter of 2026 increased by $4.1 million to $23.2 million.

Ron LatailleSVP, Treasurer and CFO

This is largely due to approximately $1.9 million in wages and benefits for back-office investments, increased members of our senior management team designed to accelerate growth, and variable compensation, as well as approximately $800,000 in non-cash equity compensation caused partially by duplicate CEO equity costs. On a sequential basis, SG&A remained relatively similar. Adjusted operating margin for the third quarter was 17.5%, and adjusted earnings per diluted share outstanding was $2.88, up significantly from last year. We generated approximately $38.5 million in cash from operations during our third quarter. Capital expenditures were $3.9 million during our third quarter, and we ended with a leverage ratio of well under one time. With that, I now turn it back to the operator for questions.

Operator

Thank you so much, sir. Ladies and gentlemen, we will now begin the question-and-answer session. To ask a question, you may press star, then one on your telephone keypad. If you are using a speakerphone, please pick up your handset before pressing the keys. If at any times your question has been addressed and you would like to withdraw your question, please press star, then two. At this time, we will pause momentarily to assemble our roster. The first question comes from the line of Justin Ages with CJS Securities. Please go ahead. Justin, you may please proceed with the question.

Justin AgesAnalyst

Yes. You mentioned strength in Patient Beds & Handling and a couple areas. Can you give us a sense on where robotic surgery growth was?

Mitch RockCEO

Good morning, Justin. How are you? Ron mentioned, we had broad growth in those four sub-segments, actually double-digit growth. As we have indicated throughout the year that 2026 is a flat to down year in robotic surgery, so the results were consistent with that.

Justin AgesAnalyst

That's helpful. Thank you, Mitch.

FULL TRANSCRIPT

Continue the full translated transcript in StockNow.

Log in to unlock every statement, the English original, and speaker-by-speaker history.

Log in for the full transcript

Other earnings calls that day

View calls from this day